NCT07150949View on ClinicalTrials.gov

Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

August 28, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2028

Conditions
Locally Advanced Rectal CancerNeoadjuvant Therapy
Interventions
RADIATION

Long-course radiotherapy

Long-course radiation: 50Gy/25Fx

DRUG

Oxaliplatin

Oxaliplatin: 130mg/m2 d1 q3w

DRUG

Capecitabine

Xeloda

DRUG

Celecoxib

celecoxib 200 mg orally twice a day

RADIATION

Short-course radiotherapy

Short-course radiotherapy: 25Gy/5Fx

DRUG

Serplulimab

Serplulimab 300mg, d1, q3w

Trial Locations (1)

200030

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT07150949 - Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) | Biotech Hunter | Biotech Hunter